Susquehanna International Group
PYXS icon

Susquehanna International Group’s Pyxis Oncology PYXS Stock Holding History

Susquehanna International Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.8K Sell
42,300
-138,000
-77% -$208K ﹤0.01% 12564
2025
Q4 		$207K Buy
180,300
+158,800
+739% +$560K ﹤0.01% 10794
2025
Q3 		$47.7K Buy
+21,500
New +$31K ﹤0.01% 11875
2025
Q1 		– Sell
-832,200
Closed -$1.3M – 13261
2024
Q4 		$1.3M Buy
832,200
+808,400
+3,397% +$2.33M ﹤0.01% 6324
2024
Q3 		$87.3K Buy
23,800
+1,400
+6% +$4.9K ﹤0.01% 11130
2024
Q2 		$74.1K Sell
22,400
-12,500
-36% -$52.6K ﹤0.01% 11215
2024
Q1 		$149K Buy
34,900
+24,400
+232% +$103K ﹤0.01% 10911
2023
Q4 		$18.9K Sell
10,500
-13,100
-56% -$22.4K ﹤0.01% 11982
2023
Q3 		$47K Sell
23,600
-3,800
-14% -$8.8K ﹤0.01% 11329
2023
Q2 		$70.1K Buy
+27,400
New +$86.9K ﹤0.01% 11180

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's PYXS Position: Q1 2026 in Review

Susquehanna International Group reduced its Pyxis Oncology (PYXS) stake by 62% in Q1 2026, selling an estimated $101K and leaving 41,201 shares worth $60.2K. The position accounts for ﹤0.01% of the portfolio, ranked #12581.

Susquehanna International Group first reported a position in PYXS in Q2 2022 and has held it in 13 quarters since. The position peaked at $383K in Q2 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Susquehanna International Group held 41,201 shares of Pyxis Oncology worth $60.2K as of Q1 2026.
  • Susquehanna International Group sold 67,213 Pyxis Oncology shares in Q1 2026, an estimated $101K.
  • Pyxis Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12581 holding.
  • Susquehanna International Group first reported a position in Pyxis Oncology in Q2 2022 and has held it in 13 quarters since.
  • Susquehanna International Group's Pyxis Oncology position peaked at $383K in Q2 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.